Baldwin Investment Management LLC Raises Holdings in Edwards Lifesciences Corporation $EW

Baldwin Investment Management LLC raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 193.2% during the third quarter, HoldingsChannel reports. The firm owned 15,085 shares of the medical research company’s stock after purchasing an additional 9,940 shares during the period. Baldwin Investment Management LLC’s holdings in Edwards Lifesciences were worth $1,173,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at about $266,000. Strategic Blueprint LLC grew its position in shares of Edwards Lifesciences by 66.0% in the second quarter. Strategic Blueprint LLC now owns 6,028 shares of the medical research company’s stock valued at $471,000 after purchasing an additional 2,397 shares in the last quarter. Sage Mountain Advisors LLC increased its holdings in shares of Edwards Lifesciences by 26.5% in the second quarter. Sage Mountain Advisors LLC now owns 3,689 shares of the medical research company’s stock valued at $289,000 after purchasing an additional 773 shares during the last quarter. Focus Partners Advisor Solutions LLC lifted its position in Edwards Lifesciences by 20.3% during the second quarter. Focus Partners Advisor Solutions LLC now owns 8,888 shares of the medical research company’s stock worth $695,000 after buying an additional 1,499 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC boosted its stake in Edwards Lifesciences by 1.7% during the second quarter. Linden Thomas Advisory Services LLC now owns 11,400 shares of the medical research company’s stock worth $892,000 after buying an additional 186 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of the stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $83.76, for a total transaction of $953,691.36. Following the sale, the vice president owned 38,970 shares of the company’s stock, valued at approximately $3,264,127.20. This represents a 22.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 43,804 shares of company stock valued at $3,699,082. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $82.54 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The firm has a market cap of $47.90 billion, a P/E ratio of 45.11, a P/E/G ratio of 2.08 and a beta of 0.94. The firm’s 50 day moving average price is $82.79 and its 200-day moving average price is $81.08. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the previous year, the firm earned $0.59 EPS. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on EW. Wells Fargo & Company raised their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a report on Monday, November 3rd. Evercore restated an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a report on Monday, January 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $100.00 price target (up previously from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.